Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-445-0 | CAS number: 7554-65-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Human clinical study, published in peer reviewed literature.
Data source
Reference
- Reference Type:
- publication
- Title:
- Effects of 4-methylpyrazole, methanol/ethylene glycol antidote, in healthy humans
- Author:
- Jacobsen D.
- Year:
- 1 990
- Bibliographic source:
- J Emerg Med. 1990 Jul-Aug;8(4):455-61.
Materials and methods
- Study type:
- study with volunteers
- Endpoint addressed:
- repeated dose toxicity: oral
- Principles of method if other than guideline:
- A placebo-controlled, double blind, multiple dose, sequential, ascending-dose study had been performed to determine the tolerance of the test substance in 5 healthy male volunteers per dose. Along with each dose group there were two placebos. Oral loading doses were followed by supplemental doses every 12 h through 5 days, producing plasma levels in the therapeutic range. Blood and urine samples were taken for haematology and clinical chemistry evaluation. Furthermore, clinical signs were registered both by the test subjects as well as by the testing personnel.
- GLP compliance:
- no
Test material
- Reference substance name:
- 4-methylpyrazole
- EC Number:
- 231-445-0
- EC Name:
- 4-methylpyrazole
- Cas Number:
- 7554-65-6
- Molecular formula:
- C4H6N2
- IUPAC Name:
- 4-methyl-1H-pyrazole
- Details on test material:
- - Name of test material (as cited in study article): 4-methylpyrazole (4-MP)
- Purity: >99.5%
Constituent 1
Method
- Type of population:
- general
- Subjects:
- Healthy males, within 15% of the normal weight range for their age (21-39 y), height, and frame size.
- Ethical approval:
- confirmed and informed consent free of coercion received
- Route of exposure:
- oral
- Reason of exposure:
- intentional
- Exposure assessment:
- measured
- Details on exposure:
- - Under double-blind conditions, subjects allowed into the study were divided into three groups. Each group randomly employed 5 subjects on the test substance and 2 on placebo.
- Group 1 received 10 mg/kg as loading dose, followed by supplemental doses of 3 mg/kg every 12 h up to 96 h.
- Group 2 received 15 mg/kg as loading dose, followed by supplemental doses of 5 mg/kg every 12 h up to 96 h.
- Group 3 received 10 mg/kg as loading dose, followed by supplemental doses of 5 mg/kg every 12 h up to 36 h, and then 10 mg/kg every 12 h up to 96 h.
- The total doses of the test substance were 34, 55, and 75 mg/kg in Groups 1, 2, and 3, respectively.
- The taste of the substance was disguised as a 0.5% (w/v) solution in a mixture of vegetable juice (V-8, Campbell Soup company), lime juice, and 6-8 drops of hot pepper sauce.
- After dosing the subjects fasted for an additional 2 h. - Examinations:
- - The monitoring of side effects was done by self-report as well as observation by testing personnel at indicated times (0, 4, 8, 12, 24, 28, 32, 36, 48, 52, 56, 60, 72, 76, 80, 84, 96, 100, 104, 108, 120, 132, and 144 h after exposure). The subjects were asked to rate all side effects on a 1 to 3 schale, where 1 was mild, 2 moderate and 3 severe. At the end of the study, each subject filled out a fixed questionnaire on which they were asked about specific side effects.
- Venous blood was drawn from a permanently inserted teflon catheter after aspiration of the heparin dead-volume. This was done at 0, 4, 8, 10, 12, 24, 28, 32, 34, 36, 48, 52, 56, 58, 60, 72, 76, 80, 82, 84, 96, 100, 104, 106, 108, 120, 132, and 144 h after exposure.
- Urine was collected at 24 h prior to exposure, and 0, 4, 8, 12, 24, 28, 32, 36, 48, 52, 56, 60, 72, 76, 80, 84, 96, 100, 104, 108, 120, 132, and 144 h after exposure.
- The laboratory parameters that were monitored: complete blood count (including differential and platelets), as standard serum chemistry screen (electrolytes, liver enzymes, proteins, lipids, glucose, BUN, and creatinine), and a complete urinalysis.
- 4-MP was analyzed in plasma and urine by modification of an HPLC method.
Results and discussion
- Clinical signs:
- Subjects side effects were reported in 3 out of 6 placebos and in 7 out of 15 drug subjects. The side effects reported at various times in both groups were dizziness, lightheadedness, diarrhea, and headache. All effects were rated mild (grade 1) and were short in duration.
- Results of examinations:
- - There were nog significant changes in objective clinical parameters such as pulse rate, body temperature, or respiratory rate in any subject at any time during the study. A mild, sporadic, and transient elevation in the blood pressure was seen in 5 of the 15 drug subjects and in 3 of the 6 placebos. The blood pressure elevation was apparently not related to test substance administration.
- The values for several of the laboratory parameters were outside of the study reference range at some measurement time in 9 of the 15 drug subjects and in 1 of the 6 placebos. One or both serum transaminase values were elevated in 6 drug subjects, but elevations were mild and had returned to normal 1-2 weeks after completion of the study. Elevation of serum cholesterol or triglyceride levels and test substance administration occurred in 3/10 drug subjects but also in 1/4 placebos
- In groups 1 and 2, the mean plasma levels of the test substance remained in the 50 to 150 µM range for about 36 to 60 h. Then the levels decreased markedly so that the test substance was detectable for only 8 h after the last administration. In group 3 the plasma levels were 100 to 200 µM and were maintained throughout the 5 day treatment.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.